10-Q: Lifeloc Technologies Reports Wider Q2 Loss Amid R&D Push

Lifeloc Technologies reported increased net losses for Q2 and the first half of 2025, driven by declining product sales and higher interest expenses, despite ongoing investment in its SpinDx drug detection technology.

Summary

• Net loss for the three months ended June 30, 2025, was ($393,639), an increase of 32% from ($297,988) in the same period last year.
• Net loss for the six months ended June 30, 2025, was ($686,325), an increase of 18% from ($581,794) in the same period last year.
• Total revenues for the three months ended June 30, 2025, decreased by 7% to $2,219,376 from $2,387,330 in the prior year.
• Total revenues for the six months ended June 30, 2025, decreased by 1% to $4,496,410 from $4,540,773 in the prior year.
• Product sales decreased by 8% for the three-month period and 1% for the six-month period.
• Gross profit margin on products remained relatively constant at 41% for the three-month period and 40% for the six-month period.
• Interest expense significantly increased due to new subordinated debentures, rising from $10,057 to $26,305 for the three-month period and from $20,207 to $50,800 for the six-month period.
• The company shifted from retained earnings of $639,863 at December 31, 2024, to a retained deficit of ($46,462) at June 30, 2025.
• Cash and cash equivalents decreased to $995,750 at June 30, 2025, from $1,243,746 at December 31, 2024.
• Net cash used in operating activities improved to ($389,576) for the six months ended June 30, 2025, compared to ($722,309) in the prior year.
• The company issued a $75,000 subordinated debenture on March 1, 2025, following a $750,000 debenture issued on December 31, 2024, both with 8.25% interest and warrants.
• Options to purchase 88,500 shares of common stock were exercised in February 2025, generating $336,300 in proceeds.

Sentiment

Score: 3

Explanation: The company reported increased net losses and declining revenues, coupled with a shift to a retained deficit, indicating weak current financial performance. While operating cash flow improved and R&D spending decreased (temporarily), the significant increase in interest expense and lack of tax benefit contributed to the worsened bottom line. The long-term strategy around SpinDx is promising but still in development, and profitability is not expected in the near term, suggesting a cautious outlook.

Positives

• Operating loss decreased for both the three months (from $397,062 to $378,265) and six months (from $777,289 to $658,813) ended June 30, 2025, compared to the prior year.
• Net cash used in operating activities significantly improved to ($389,576) for the six months ended June 30, 2025, from ($722,309) in the prior year.
• Net cash used in investing activities decreased to ($242,251) for the six months ended June 30, 2025, from ($512,999) in the prior year.
• Royalties increased to $19,800 for the three months and $25,471 for the six months ended June 30, 2025, due to increased sales by royalty-paying customers.
• Research, development, and sustaining engineering expenses decreased by 6% for the three-month period and 10% for the six-month period, primarily due to timing of outside contractor services.
• The company successfully raised capital through the issuance of subordinated debentures ($75,000 in March 2025, $750,000 in December 2024) and the exercise of stock options ($336,300 in February 2025).
• Advancement of SpinDx technology, with beta testing with human subjects set to begin in partnership with Anschutz Medical Center in Colorado.
• The company plans to expand into the full corporate headquarters space following the expiration of its tenant's lease on June 30, 2025.

Negatives

• Net loss increased by 32% for the three months ended June 30, 2025, to ($393,639) and by 18% for the six months ended June 30, 2025, to ($686,325).
• Product sales decreased by 8% for the three-month period and 1% for the six-month period, attributed to the absence of larger orders and inflationary pressures on customer budgets.
• The company transitioned from retained earnings of $639,863 at December 31, 2024, to a retained deficit of ($46,462) at June 30, 2025.
• Cash and cash equivalents decreased by $247,996 to $995,750 at June 30, 2025, from $1,243,746 at the beginning of the period.
• Interest expense significantly increased due to new subordinated debentures, rising from $10,057 to $26,305 for the three-month period and from $20,207 to $50,800 for the six-month period.
• No benefit from federal and state income taxes was recognized in the current periods, compared to benefits of $100,454 and $189,353 in the prior year periods, respectively.
• General and administrative expenses increased by 7% for the six months ended June 30, 2025, due to various increased expenses.
• Operating losses are expected to continue in 2025 as the company works toward the commercialization of SpinDx.

Risks

• There is no assurance that increased marketing efforts, new product introductions, or sales network expansion will result in increased sales or continuing profitable operations.
• The company has incurred operating losses in 2021 through 2024, and these losses are continuing in 2025, with no assurance that future operating losses will not occur.
• Orders for all products, particularly ignition interlock components, are on an intermittent purchase order basis, with no assurance of continuation at any given rate or repetition of orders.
• Quarter-to-quarter revenue fluctuations are expected to continue due to the unpredictable timing and size of large customer orders.
• If the company is unable to manage business operations in line with budget expectations, it could have a material adverse effect on business viability, financial position, results of operations, and cash flows.
• If the company is not successful in regaining profitability and remaining at least cash flow break-even, additional borrowings or capital may be required to maintain ongoing operations.
• If revenue levels prior to 2020 do not continue to increase in a timely manner, if inflationary pressures are not contained, or if the development and market acceptance of SpinDx takes longer than expected, the company may be required to seek additional sources of capital and/or implement further cost reduction measures.

Future Outlook

The company expects to increase sales in the U.S. and worldwide through its growing network of direct customers and distributors, focusing on expanding global reach and broadening its product offering in alcohol and drug detection. Operating losses are anticipated to continue in 2025 as efforts are concentrated on the commercialization of SpinDx, with a commercial launch expected in 2026. Research and development expenses are projected to be maintained through 2025 and then reduced upon completion of the new product line. Sales and marketing expenses are expected to increase with expanded direct sales and marketing efforts. Revenues for the remainder of 2025 may be similar to 2024, and the company believes its cash resources will be sufficient to fund operations for the next twelve months under its current operating plan.

Management Comments

• "We believe the installed base of our breathalyzers will increase as the inherent risks associated with drinking while driving or while working in safety sensitive jobs become more widely acknowledged and as our network of distributors and our direct sales force grows."
• "We believe that increased marketing efforts, the introduction of new products and the expansion of our sales network may provide the basis for increased sales and continuing profitable operations."
• "Operating losses are continuing in 2025 and we expect them to continue as we continue to work toward the commercialization of SpinDx."
• "With the introduction of new products, we believe Lifeloc will again be profitable."
• "We believe that cash resources will be sufficient to fund our operations for the next twelve months under our current operating plan."
• "We believe that the diminishing of the Covid-19 pandemic, the resolution of supply chain issues, and the introduction of several new products during the last several years, along with new and on-going customer relationships will allow Lifeloc to operate profitably."

Industry Context

Lifeloc Technologies operates in the highly technical, competitive, and price-driven breath alcohol testing instrument market, serving law enforcement, workplace, corrections, OEM, and consumer segments. The company is strategically expanding into the drug detection market with its SpinDx technology, which aims to offer a unique advantage by isolating psychoactive delta-9-THC for more accurate impairment detection, particularly relevant for marijuana testing. This move positions Lifeloc to address evolving market needs and potentially enter new growth areas where current solutions are lacking. The industry is subject to regulations from bodies like the U.S. Department of Transportation, which can impact product development costs and timelines.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards. It highlights SpinDx's unique advantage in isolating psychoactive delta-9-THC from inactive metabolites, which is a key differentiator in the evolving drug testing landscape, especially for marijuana impairment detection, where competitive devices may yield false positives.

Management Changes

Corporate Governance

Legal Proceedings

• The company was not involved or party to any legal proceedings at June 30, 2025, or December 31, 2024, and therefore made no accruals for legal proceedings in either period.

Related Party Transactions

• In July 2024, the company completed a private placement of 210,000 shares of common stock at $3.80 per share for a total of $798,000 with a related party.
• In February 2025, the President and CEO exercised 37,500 options to purchase common stock.
• Two directors exercised 1,000 options each in February 2025.
• EDCO Partners, LLLP, of which the CFO and board chairman is the general partner, provided $132,240 to enable 19 option holders (including a third director and an entity controlled by the CFO and board chairman) to exercise and simultaneously sell their shares to EDCO Partners.

Stakeholder Impact

• Shareholders: Experienced increased net losses and a shift to a retained deficit, potentially impacting shareholder value. However, capital raises through debentures and option exercises provided funding, and the long-term potential of SpinDx offers future upside.
• Employees: Key management and other employees benefited from stock option exercises, indicating alignment of interests.
• Customers: May face continued inflationary pressures on product costs. The company's focus on new product development (SpinDx) and maintaining high customer service aims to benefit customers in the long term.
• Creditors: New subordinated debentures increased the company's debt burden and interest expense, but also provided necessary capital. The term loan is secured by the company's building.
• Suppliers: Inflationary pressures are increasing the cost of raw materials, which could impact supplier relationships and pricing.

Next Steps

• Begin beta testing of SpinDx with human subjects in partnership with Anschutz Medical Center in Colorado.
• Commercial launch of SpinDx expected in 2026, starting with a saliva-based system, followed by blood and breath sample capabilities.
• Expand into the full corporate headquarters space following the expiration of the tenant lease on June 30, 2025.
• Maintain research and development expenses through 2025, then begin to reduce them as the new product line development completes.
• Increase direct sales representatives and marketing efforts.
• Focus development efforts on products offering the best prospects to increase intermediate and near-term revenues, with particular emphasis on completing SpinDx.
• Continue to pursue acquisitions aligned with the mission to deliver near and remote sensing and monitoring solutions.

Key Dates

Recommendation

While the company reported increased net losses and a shift to a retained deficit, indicating weak current financial performance, there are strategic initiatives that warrant a 'Hold' rather than 'Sell.' The company is actively investing in the SpinDx drug detection technology, which has a unique competitive advantage and is expected to launch in 2026. This represents a significant future growth opportunity. Additionally, the company has successfully raised capital through debentures and option exercises, and cash flow from operations improved compared to the prior year. However, the immediate financial results are weak, and profitability is not expected in the near term, suggesting caution. Investors should monitor the progress of SpinDx development and the company's ability to return to profitability.

Keywords

Breathalyzers, Alcohol Testing, Drug Detection, SpinDx, Law Enforcement, Workplace Safety, OEM, Portable Breath Alcohol Testing, SEC Filing, Quarterly Report, Financial Results, LCTC, Medical Devices, Diagnostics